EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, bioAffinity Technologies's Enterprise Value is $3.10 Mil.
bioAffinity Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.93 Mil. Therefore, bioAffinity Technologies's EV-to-FCF for today is -0.28.
The historical rank and industry rank for bioAffinity Technologies's EV-to-FCF or its related term are showing as below:
BIAF'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.09 Med: -1.19 Max: 1.74
Current: -0.28
During the past 6 years, the highest EV-to-FCF of bioAffinity Technologies was 1.74. The lowest was -13.09. And the median was -1.19.
BIAF's EV-to-FCF is ranked worse than 100% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.53
vs BIAF: -0.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
bioAffinity Technologies's PE Ratio (TTM) for today is calculated as:
bioAffinity Technologies's share price for today is $0.7599.
bioAffinity Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.347.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
bioAffinity Technologies EV-to-FCF Related Terms
bioAffinity Technologies EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, bioAffinity Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's EV-to-FCF falls into.
bioAffinity Technologies's current Enterprise Value is $3.10 Mil.
bioAffinity Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (BIAF) has a EV-to-FCF of -0.28 as of Jul. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on bioAffinity Technologies and its competitors. According to the industry distribution chart, bioAffinity Technologies ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry.
Is bioAffinity Technologies' EV-to-FCF too high?
bioAffinity Technologies' current EV-to-FCF is -0.28. Based on the distribution chart, bioAffinity Technologies ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' EV-to-FCF compare to NDRA and ISPC?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #999999 out of 98 companies for EV-to-FCF. This places bioAffinity Technologies in the lower half of its industry. The industry median EV-to-FCF is 23.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 23.53, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on bioAffinity Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 23.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current EV-to-FCF is -0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $0.76 — trading 82.2% below its estimated fair value. The current EV-to-FCF is -0.28. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current EV-to-FCF is -0.28 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.27.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
EV-to-FCF: -0.28
GF Value™: $4.27 vs. price of $0.76 (82.2% below fair value)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 
